Here we present findings, using data from the BRCA-DIRECT Study, on the uptake, utilisation and resource requirements for management of a TH alongside the BRCA-DIRECT digital pathway, implemented within five breast oncology units based within London and Manchester, for diagnostic genetic testing of BRCA1, BRCA2 and PALB2 in unselected patients with BC. The gene discussed is PALB2; the disease is breast cancer.